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Gonadotropin receptors belong to the super family of G protein-coupled receptors and 
mediate the physiological effects of follicle-stimulating hormone (FSHR) and luteinizing 
hormone (LHR). Their central role in the control of reproductive function has made them 
the focus of intensive studies. Upon binding to their cognate hormone, they trigger 
complex signaling and trafficking mechanisms that are tightly regulated in concentration, 
time, and space. Classical cellular assays often fail to capture all these dynamics. Here, 
we describe the use of various bioluminescence and fluorescence resonance energy 
transfer (BRET and FRET) assays to investigate the activation and regulation of FSHR 
and LHR in real-time, in living cells (i.e., transiently expressed in human embryonic kidney 
293 cells). Indeed, the dynamics of hormone-mediated heterotrimeric G protein activa-
tion, cyclic adenosine-monophosphate (cAMP) production, calcium release, β-arrestin 
2 recruitment, and receptor internalization/recycling was assessed. Kinetics and dose–
response analyses confirmed the expected pharmacological and signaling properties 
of hFSHR and hLHR but revealed interesting characteristics when considering the two 
major pathways (cAMP and β-arrestin 2) of the two receptors assessed by BRET. Indeed, 
the EC50 values were in picomolar range for cAMP production while nanomolar range 
was observed for β-arrestin 2 recruitment as well as receptor internalization. Interestingly, 
the predicted receptor occupancy indicates that the maximal G protein activation and 
cAMP response occur at <10% of receptor occupancy whereas >90% of activated 
receptors is required to achieve full β-arrestin 2 recruitment and subsequent receptor 
internalization. The rapid receptor internalization was also followed by a recycling phase. 
Collectively, our data reveal that β-arrestin-mediated desensitization, internalization, 
and the subsequent fast recycling of receptors at the plasma membrane may provide 
a mechanistic ground to the “spare receptor” paradigm. More generally, the novel tools 
described here will undoubtedly provide the scientific community investigating gonado-
tropin receptors with powerful means to decipher their pharmacology and signaling with 
the prospect of pathophysiological and drug discovery applications.
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introduction
The gonadotropin receptors play a central role in the control 
of mammal reproduction by mediating the physiological 
responses of the two major pituitary glycoprotein hormones, 
follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH). Their respective receptors, follicle-stimulating hormone 
receptor (FSHR) and luteinizing hormone receptor (LHR), are 
mainly expressed in the gonads where they control the ovarian 
and testicular functions in females and males, respectively, by 
regulating both steroidogenesis and gametogenesis (1, 2). Both 
FSHR and LHR belong to a subgroup of class A (rhodopsin-like) 
G protein-coupled receptors (GPCRs) characterized by the pres-
ence of multiple leucine-rich repeats (LRRs) in their extracellular 
amino-terminal domain. This subgroup also includes the thyroid-
stimulating hormone receptor (TSHR) and the receptors for the 
peptidic hormone relaxin and INSL3 (RXFP1 and 2). The LRRs 
containing region in FSHR has been shown to be determinant 
for its interaction with FSH (3–5). In terms of the intracellular 
signaling, FSHR and LHR are known to mediate the canoni-
cal G protein-mediated signaling pathway through coupling 
to heterotrimeric Gαs proteins, which activates the adenylate 
cyclase, resulting in an increase in intracellular cyclic adenosine-
monophosphate (cAMP) levels and activation of protein kinase 
A (PKA) as well as the exchange protein directly activated by 
cAMP (EPAC). This in turn triggers the activation of multiple 
downstream kinases that modulate the nuclear activity of cAMP 
response element-binding protein (CREB) and the expression of 
the genes involved in the physiological responses of the gonado-
tropins. However, recent evidences point to a multiplicity of the 
signaling that can be mediated by FSHR and LHR by engaging 
additional G protein-dependent and independent pathways [for 
review, see Ref. (6–9)], including β-arrestin-dependent pathways 
(10–13). As a consequence, similar to most other GPCRs, these 
receptors’ pharmacology and signaling involve highly diverse and 
complex mechanisms. Therefore, the use of recent innovative 
technologies to investigate these receptors could certainly help 
understanding better their activation mode.
Among the emerging methods to study GPCRs, the focus is on 
energy transfer-based assays that rely on the biophysical biolumi-
nescence and fluorescence resonance energy transfer (BRET and 
FRET) technologies. These approaches link the concept of dis-
tance/proximity, in space and time, between an energy donor and 
an energy acceptor to the biological question of interest accord-
ing to Förster’s Law in both static and dynamic configurations 
(14–16). Since their development, BRET and FRET have been 
extensively used to study different cellular and molecular aspects 
related to the function and regulation of cell surface receptors, 
such as GPCRs and tyrosine kinase receptors (TKRs) (17, 18). In 
fact, GPCRs constitute the research field of choice where BRET/
FRET are elegantly used and are being the subject of permanent 
development and improvement (16, 19–21). Indeed, by using 
BRET and FRET, it is now possible to quantitatively address, in 
real-time and live cells, different questions about the functioning 
of GPCRs including ligand binding, receptor activation, G protein 
coupling, intracellular downstream signaling, β-arrestin recruit-
ment, receptor trafficking, and oligomerization (16, 19–26). In 
this context, BRET and FRET significantly contributed to major 
recent advances in the field with the emergence of new concepts, 
such as receptor heteromerization, receptor/G protein preas-
sembly, and biased signaling. Even though these advances further 
illustrate the complexity of the GPCR functioning, they pushed 
the scientific community one step further in understanding better 
the involvement of GPCRs in physiology and pathophysiology. 
However, the application of BRET and FRET approaches to the 
gonadotropin receptors has remained limited to date. In this 
study, we report the application of a series of novel BRET and 
FRET assays to study the activation and regulation of the human 
gonadotropin receptors, hFSHR and hLHR/hCGR (here designed 
as hLHR), when they are transiently expressed in HEK 293 cells. 
Kinetics and dose–response analyses using various assays were 
performed in 96- and 384-well formats in real-time and live cells.
Materials and Methods
Materials and Plasmid constructions
The plasmid encoding human FSHR was generated as previously 
described (12). The other plasmids encoding the different BRET/
FRET sensors and fusion proteins were generously provided as 
follows: hLHR from A. Ulloa-Aguirre (Universidad Nacional 
Autónoma de México, México, Mexico), different Rluc8- and 
Venus-fused G proteins from J. P. Pin (Functional Genomics 
Institute, Montpellier, France) and K. D. Pfleger (Harry Perkins 
Institute of Medical Research, Perth, WA, Australia) (also hV2R–
Rluc8), Rluc8-fused hFSHR and hLHR from A. Hanyaloglu 
(Imperial College, London, UK), yPET-β-arrestin 2 from M. 
G. Scott (Cochin Institute, Paris, France), Aequorin-GFP from 
B. Lambolez (Pierre et Marie Curie University, Paris, France), 
CAMYEL from L. I. Jiang (University of Texas, TX, USA), ICUE 
from J. Zhang (The Johns Hopkins University, Baltimore, MD, 
USA), and Venus-KRas from N. A. Lambert (Georgia Health 
Sciences University, Augusta, GA, USA). Recombinant hFSH 
was kindly gifted by Merck-Serono (Darmstadt, Germany), 
hCG was kindly donated by Y. Combarnous (CNRS, Nouzilly, 
France), forskolin and DDAVP were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All the 96- and 384-well white 
microplates were from Greiner Bio-One (Courtaboeuf, France). 
Coelenterazine h substrate was purchased from Interchim 
(Montluçon, France).
cell culture and Transfection
HEK 293 cells were grown in complete medium (DMEM sup-
plemented with 10% (v/v) fetal bovine serum, 4.5 g/l glucose, 
100  U/ml penicillin, 0.1  mg/ml streptomycin, and 1  mM 
glutamine) (all from Invitrogen, Carlsbad, CA, USA). Transient 
transfections were performed by reverse transfection in 96-well 
plates using Metafectene PRO (Biontex, München, Germany) 
following the manufacturer’s protocol. Briefly, for each well, the 
different combinations of coding plasmids were used as follows: 
200 ng of total plasmid per well were resuspended in 25 μl of 
serum-free DMEM and mixed with Metafectene PRO (0.5 μl/
well) previously preincubated 5  min at room temperature in 
25 μl serum-free DMEM (2 × 25 μl/well). Then the two solutions 
of serum-free DMEM-containing plasmids and Metafectene 
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PRO were mixed and incubated for 20 min at room temperature. 
Cells (105 in 200 μl/well) in DMEM supplemented with 10% FCS 
were then incubated with the final plasmid-Metafectene PRO 
mix (50  μl/well). Transfection efficiency was typically in the 
60–70% range and the correct expression of the different fusion 
proteins used for BRET and FRET was examined by fluores-
cence and luminescence measurements using a Mithras LB 943 
plate reader (Berthold Technologies GmbH and Co. Wildbad, 
Germany).
BreT Measurements
Forty-eight hours after transfection, cells were washed with 
PBS and BRET measurements were performed depending on 
the experiments as described previously (27). For the endpoint 
dose–response analysis, cells were first preincubated 30  min 
at 37°C in 40 μl/well of PBS 1×, HEPES 5 mM, 200 μM IBMX 
(for cAMP assays) containing or not increasing concentrations 
of hFSH or hCG as indicated. Then BRET measurements were 
performed upon addition of 10  μl/well of coelenterazine h 
(5 μM final) using a Mithras LB 943 plate reader. For the real-
time BRET kinetics, cells were first resuspended in 60 μl/well 
of PBS-HEPES 10 mM (+IBMX 200 μM for cAMP assays) and 
then BRET measurements were immediately performed upon 
addition of 10 μl/well of coelenterazine h (5 μM final) and 10 μl/
well of the sub-maximal concentrations of hFSH or hCG (fivefold 
concentrated).
calcium Measurements Using aequorin-gFP
Forty-eight hours after transfection, cells co-expressing 
hFSHR and aequorin-GFP (AEQ-GFP) were incubated for 3 h 
with 40 μl/well of coelenterazine h substrate (5 μM final) in 
PBS 1×, HEPES 10 mM, BSA 0.1%, in the dark, and at 37°C 
to allow aequorin reconstitution. Luminescence emission at 
480 and 540 nm was then measured in each well individually 
every 0.05 s before and after the rapid injection of 10 μl/well of 
hFSH (fivefold concentrated) or of vehicle, using the injection 
system and the dual emission detection of a Mithras LB 943 
plate reader.
caMP accumulation Measured by hTrF ®
Intracellular cAMP levels were measured using a homogeneous 
time-resolved fluorescence (HTRF ®) cAMP dynamic 2 assay 
kit (CisBio Bioassays, Bagnol sur Cèze, France) (28). Forty-
eight hours post-transfection cells were detached and seeded 
into white 384-well microplates with 5,000 cells/well in 5  μl 
of stimulation buffer (PBS 1×, 200 μM IBMX, 5 mM HEPES, 
0.1% BSA). For their stimulation, 5 μl/well of the stimulation 
buffer containing or not different doses of hFSH and hCG as 
indicated were added. Then, cells were incubated for 30  min 
at 37°C and then lysed by addition of 10 μl/well of the sup-
plied conjugate-lysis buffer containing d2-labeled cAMP and 
Europium cryptate-labeled anti-cAMP antibody, both recon-
stituted according to the manufacturer’s instructions. Plates 
were incubated for 1  h in the dark at room temperature and 
time-resolved fluorescence signals were measured at 620 and 
665 nm, respectively, 50 ms after excitation at 320 nm using a 
Mithras LB 943 plate reader.
caMP accumulation Measured by Microscopic 
FreT assay
Forty-eight hours after transfection, cells co-expressing the 
cAMP sensor (ICUE) with either hFSHR or hLHR were plated in 
imaging dishes and imaged in the dark at 37°C on a temperature-
controlled stage using a Leica DM IRB (Leica Microsystems) 
microscope with a CoolSnap fx cooled charge-coupled device 
camera (Ropper Scientific) controlled by METAFLUOR 7.5 
(Universal Imaging Corporation, Downingtown, PA, USA). 
Dual emission ratio imaging was carried out using a 436DF10 
excitation filter, a 436–510 DBDR dichroic mirror, and 480-AF30 
and 550-AF30 emission filters for CFP and YFP, respectively. 
Exposure time was 400  ms and images were taken every 30  s. 
Typically, equal sensor-positive cells and non-specific areas 
were chosen in the field of the microscope. The evolution of 
fluorescence was recorded individually in each area for the whole 
duration of the experiments. Several independent plates were 
analyzed according to this procedure, and the specific FRET 
signal of each cell (positive minus negative area) was pooled. 
Cells displaying a whole range of intensities were selected and 
analyzed without any impact of the expression level of the sensor 
on the responsiveness being noticed. After 5  min of baseline 
measurement, cells were stimulated with either 1 nM of hFSH or 
hCG, and 1 μM of forskolin was added as a positive control after 
20 min of stimulation. A low hormone dose has been chosen in 
order to avoid saturation of the ICUE sensor, which has a limited 
dynamic range compared to BRET assays. Fluorescent intensity 
of non-specific areas was subtracted to the intensity of fluorescent 
cells expressing the sensor in order to quantify the specific signal. 
The FRET ratio (CFP/YFP) was calculated for each individual 
cell. Data represent the mean ± SEM of at least 20 individual cell 
responses measured in three independent experiments.
β-arrestin recruitment assessed by  
TangO assay
This assay was carried out as previously described by Barnea 
et al. (29). We generated HTLA cells (HEK293T-derived cell line 
containing a stably integrated tTA-dependent firefly luciferase 
reporter gene) stably expressing FSHR/AVPR2-CT chimera, and 
β-arrestin 2-TEV fusion protein. Growing HTLA hFSHR cells 
were plated in white 96-well assay plates at 4 × 104 cells per well 
in MEM, supplemented with 10% FBS, glutamine, and antibiotic 
cocktail. Twenty-four hours after plating, increasing concentra-
tions of hFSH were added and cells were cultured for 14–20 h 
before measuring reporter gene activity. Luciferase activity was 
determined by using the Bright-Glo luciferase assay system 
(Promega, Charbonnieres, France), following the manufacturer’s 
protocol, and using a POLARstar OPTIMA luminometer (BMG 
Labtech, Ortenberg, Germany).
Data analysis
Bioluminescence resonance energy transfer data are represented 
either as 480  nm/540  nm (ICUE sensor), 540  nm/480  nm 
(β-arrestin and internalization kinetics), or as hFSH/hCG-
induced BRET changes by subtracting the ratio 540 nm/480 nm 
of luminescence in a well of PBS-treated cells from the same 
ratio in wells where the cells were treated with hFSH or hCG. In 
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this calculation, only ligand-induced BRET changes (increase or 
decrease) are represented and the PBS-treated cell sample repre-
sents the background eliminating the requirement for measuring 
an Rluc-only control sample since fast kinetics and dose–response 
analyses were performed. Kinetic and dose–response curves were 
fitted following the appropriate non-linear regression equations 
using Prism GraphPad software (San Diego, CA, USA). Statistical 
analyses were performed using two-way ANOVA included in 
Prism GraphPad software.
results
receptor-Mediated caMP Production
First, we examined cAMP response by hFSHR and hLHR since 
they are both known to couple to heterotrimeric Gs protein, lead-
ing to adenylyl cyclase activation and ultimately to an increase 
in the intracellular cAMP levels. To this end, we used the BRET-
based cAMP sensor, CAMYEL, developed by Jiang et  al. (30) 
(Figure 1A), which allows the assessment of intracellular cAMP 
changes in real-time and live cells. Under basal conditions, a 
high-BRET signal occurs between the donor (Renilla luciferase 
or Rluc) and the acceptor (green fluorescent protein or GFP) due 
to the favorable conformation and proximity/orientation of the 
Rluc and GFP within the Epac motif composing the sensor. In 
contrast, an increase in the cytosolic cAMP concentrations and 
its binding to Epac induce changes in the conformation of Rluc-
Epac-GFP sensor, resulting in a significant decrease in the BRET 
signal (Figure 1A). The receptors were transiently co-expressed 
with CAMYEL in HEK 293 cells and real-time kinetics were con-
ducted (Figures 1B,C) at different doses allowing the inference of 
sigmoidal dose–response curves (Figures 1D,E). Kinetic analyses 
showed a relatively fast cAMP response (t1/2 of 3.2 and 1.7 min for 
FSHR and LHR, respectively) (Table 1) upon stimulation with 
5 nM of gonadotropins with a plateau reached after ~10 min for 
both hFSHR (Figure 1B) and hLHR (Figure 1C). As expected, 
both hormones, hFSH (Figure 1D) and hCG (Figure 1E), showed 
very potent effects on their specific receptors with EC50 values in 
the picomolar range (Table 1). Similar results were obtained using 
HTRF®-based cAMP assay (28) on both hFSHR (Figure 1F) and 
hLHR (Figure 1G) either wildtype or Rluc8-fused receptors. This 
indicates that both Rluc8-fused receptors retained correct expres-
sion and function and can therefore be used in BRET assays 
for the recruitment of β-arrestin 2 and receptor internalization 
(Figures 5 and 6).
We also used a FRET-based cAMP sensor (ICUE) allowing 
real-time measurements of cAMP production as previously 
shown (31) (Figure  2A) using both real-time FRET measure-
ments in 96-well plate format every 0.5 s as well as individual cell 
analysis with the appropriate fluorescence microscopy setting. 
The 96-well plate format clearly allowed to measure very rapid 
changes in the FRET signals in cells co-expressing ICUE and 
hFSHR and challenged with 1 μM of forskolin (Figure  2B) or 
5 nM of hFSH (Figure 2C). These changes were specific to hFSH/
forskolin-induced cAMP production since vehicle injection did 
not induce any change in the FRET signal (Figure 2D). In paral-
lel, the FRET analysis by fluorescence microscopy on individual 
stimulated cells co-expressing ICUE and either hFSHR or hLHR 
showed a time-dependent increase of cAMP production induced 
by 1 nM of hFSH or hCG, respectively, as well as 1 μM of forskolin 
(Figure 2E), as previously reported (12).
receptor-gαs Protein coupling assessed 
by BreT
Next, we examined the functional coupling of hFSHR and hLHR 
to the heterotrimeric G protein (Gαs and Gβγ) in real-time and 
live cells by measuring BRET changes between the different G 
protein subunits as previously reported (27, 32–36). In this assay, 
a change (in this case a decrease) in the proximity/association 
between the Gα subunit and Gβγ dimer as well as their confor-
mation upon receptor activation is assessed in time-dependent 
manner reflecting the functional coupling of the receptor with 
its cognate heterotrimeric G protein (Figure 3A). Gαs-Rluc8 was 
transiently co-expressed with either Venus-Gγ2 (Figures 3B,C) 
or Venus-Gβ1 (Figures 3D,E) in the presence of hFSHR or hLHR 
as indicated. BRET changes were then rapidly assessed every 0.5 s 
before and after receptor activation by the injection of 10 nM of 
hFSH or hCG. As shown, hFSH nicely induced a very rapid and 
significant BRET decrease between Gαs-Rluc8 and Venus-Gγ2 
(Figure  3B) and Venus-Gβ1 (Figure  3D) co-expressed with 
hFSHR. Similar albeit noisier effects were observed with 10 nM of 
hCG on BRET between Gαs-Rluc8 and Venus-Gγ2 (Figure 3C) 
and Venus-Gβ1 (Figure 3E) in the context of hLHR expressing 
cells. Such BRET changes likely reflect the activation of Gαs pro-
tein by the hFSHR and hLHR and are consistent with the cAMP 
measurements shown in Figures 1 and 2. Our data are consistent 
with the previous BRET data reported for other GPCRs, showing 
a decrease of the BRET signals between Gαs and Gβ/γ subunits 
(32, 33, 35, 36). As expected, the observed kinetics with these 
sensors was much faster than the one measured for cAMP (i.e., 
t1/2 between 10 and 16 s) (Table 1).
receptor-Mediated calcium release
We also assessed the intracellular calcium release mediated by 
the activation of gonadotropin receptors as previously reported 
(37, 38). For this, we used an aequorin-dependent calcium assay 
(AEQ-GFP) based on luminescence and BRET increase upon 
binding of calcium to the aequorin protein fused to GFP (39, 40) 
(Figure 4A). In the presence of calcium, aequorin emits lumines-
cence at 480 nm part of which is transferred to GFP due to their 
sufficient proximity leading to GFP excitation and light emission 
at 540 nm. As shown in Figure 4B, in cells co-expressing AEQ-
GFP and hFSHR, a significant and rapid increase in light emission 
at 540 nm occurred upon cell stimulation with 10 nM of hFSH 
(Figure 4B) indicating intracellular calcium increase. However, 
in cells co-expressing AEQ-GFP and hLHR, a significant basal 
emission at 540 nm was observed and stimulation with 10 nM 
hCG only induced weaker response (Figure 4C) as compared to 
hFSH on its receptor (Figure 4B). Such an effect was specific to 
gonadotropins since no increase in light emission was observed 
in AEQ-GFP and hFSHR co-expressing cells upon vehicle injec-
tion (Figure 4D) and the hFSH-promoted luminescence increase 
was dose-dependent (Figure 4E). Moreover, no significant light 
emission was measured in cells expressing AEQ-GFP alone and 
stimulated with 10 nM of hFSH (data not shown).
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recruitment of β-arrestin 2 assessed by BreT
The role of β-arrestins not only in desensitization/internalization 
but also in signaling of GPCRs is now well established (41–43) 
and this has been previously reported for the FSHR (10, 11, 13, 44) 
and LHR (45). Here, we examined for the first time the recruitment 
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FigUre 1 | BreT- and hTrF-based caMP production assays.  
(a) Principle of the BRET-based cAMP assay (CAMYEL sensor). HEK 293 cells 
transiently expressing the indicated proteins (wildtype receptors and CAMYEL 
for BRET; wildtype or Rluc8-tagged receptors for HTRF) were stimulated with 
either 5 nM (for kinetics) or increasing concentrations (for dose–response 
curves) of hFSH (B,D,F) or hCG (c,e,g) as indicated. Then BRET and HTRF 
measurements format were performed as described in the Section “Materials 
and Methods” in 96-well and 384-well plates, respectively. Data are 
means ± SEM of three experiments performed either in a single point or 
triplicate.
of β-arrestins to activated hFSHR and hLHR in real-time and live 
cells using BRET technology as illustrated in Figure 5A. Indeed, 
under the inactive conformation of the receptors, β-arrestins are 
mostly cytosolic. Upon activation, the receptors are phosphoryl-
ated by G protein-coupled receptor kinases (GRKs) leading to 
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the translocation of β-arrestins from the cytosol to the intracel-
lular domains of the receptors triggering their desensitization, 
internalization, and signaling. The BRET increase between the 
receptors and β-arrestins is used to assess this process in real-time 
and living cells. For this purpose, the receptors were fused to 
BRET donor (Receptor-Rluc8) and co-expressed with β-arrestin 
2 fused to BRET acceptor (here yPET as a GFP variant) and the 
translocation of β-arrestin 2 to the receptor was then measured 
before and after receptor activation (Figure 5A). The functionality 
of FSHR-Rluc8 and hLHR-Rluc8 is verified by the cAMP assay 
shown in Figures 1F,G. Dose–response and kinetics experiments 
were carried out in cells co-expressing yPET-β-arrestin 2 and either 
hFSHR-Rluc8 (Figures  5B,E) or hLHR-Rluc8 (Figures  5C,F). 
Real-time kinetic analyses showed a significant BRET increase 
over the basal signal with hFSHR-Rluc8 (Figure  5B) or hLHR-
Rluc8 (Figure 5C) and yPET-β-arrestin 2 upon stimulation with 
10 nM of hFSH or hCG, respectively. The BRET increase occurred 
in a time-dependent manner with a sustained plateau reached after 
20–30 min of receptor activation indicating a class B profile accord-
ing to the common GPCR classification with respect to β-arrestin 
association (46). We used the human vasopressin V2 receptor 
(hV2R–Rluc8) as a prototype for class B GPCR in our BRET assay 
and observed a similar kinetic profile compared to hFSHR and 
hLHR (Figure 5D). Moreover, the effects were dose-dependent for 
both hFSH (Figure 5E) and hCG (Figure 5F) on their respective 
receptors with EC50 values largely higher (i.e., nanomolar range) 
than those observed for cAMP signaling (Figure 1; Table 1). Such 
shift in the hormone potencies is not due to the effect of fusion 
of the receptors with Rluc8 since these constructs showed cAMP 
responses similar to that observed with their corresponding wild 
type receptors (Figures 1F,G). Moreover, dose–response experi-
ments were also performed using an indirect TANGO assay on 
hFSHR bearing the vasopressin receptor 2 (V2R) C-terminus and 
showed similar potency of hFSH on hFSHR/β-arrestin 2 associa-
tion as assessed by BRET (Figure 5G).
receptor internalization and recycling 
assessed by BreT
Finally, we examined gonadotropin-induced receptor internali-
zation in real-time and live cells using BRET between the Rluc8-
tagged receptors (BRET donor) and a plasma membrane marker, 
KRas, fused to BRET acceptor (Venus, another GFP variant), as 
recently described (47). This assay is based on the changes in the 
TaBle 1 | ec50 and t1/2 values for gonadotropin-promoted caMP production, β-arrestin 2 recruitment and receptor internalization/recycling of hFshr 
and hlhr.
receptors caMP production BreT g 
proteins
β-arrestin 2 recruitment internalization recycling
ec50 (pM)  
BreT
ec50 (pM)  
hTrF
t1/2 (min)  
BreT
t1/2 (s)  
BreT
ec50 (nM)  
BreT
ec50 (nM) 
TangO
t1/2 (min)  
BreT
ec50 (nM)  
BreT
t1/2 (min)  
BreT
hFSHR 3.0 ± 1.2 1.4 ± 0.1 3.2 ± 0.3 16.8 ± 11.7a 3.7 ± 2.0* 5.7 ± 2.6* 4.8 ± 0.3 2.6 ± 1.0* 10.5 ± 0.2
10.9 ± 0.3b
hLHR 3.5 ± 2.2 1.9 ± 0.3 1.7 ± 0.1 ND 2.0 ± 0.1 ND 6.6 ± 0.2 4.9 ± 1.9 8.6 ± 0.3
Data are means ± SEM of three to four independent experiments.
aBRET between Gαs-Rluc8 and Venus-Gγ2.
bBRET between Gαs-Rluc8 and Venus-Gβ1, both calculated by fitting the curves in Figures 3B,D using “plateau then one phase decay equation.”
*p < 0.05 versus EC50 values measured in cAMP production assay.
physical proximity between KRas and the receptors at the plasma 
membrane upon receptor activation and thereby internalization 
as illustrated in Figure 6A. The agonist-induced decrease in the 
high basal BRET signals was assessed in cells co-expressing Venus-
KRas with either hFSHR-Rluc8 or hLHR-Rluc8 (Figure  6A). 
We observed a very rapid decrease in the BRET signal between 
hFHSR-Rluc8 and Venus-KRas following cell stimulation with 
10 nM of hFSH to reach the maximal decrease up to 2–5 min post-
stimulation, indicating the rapid internalization of hFSHR under 
our conditions (Figure 6B). Interestingly, we observed a recovery 
phase of the BRET signal after 5–10 min of stimulation, which 
returns back to the basal level after 20 min suggesting recycling 
of the internalized receptors (Figure 6B). To confirm this obser-
vation on both hFSHR and hLHR, we performed time-course 
analysis where cells were first preincubated with hFSH or hCG at 
different times at 37°C before BRET signals were measured. The 
BRET measurements showed a maximal internalization of both 
receptors after 2–5 min and a total recovery of the BRET signals 
after 20 min (Figure 6C). Interestingly, the recovery phase con-
tinued to increase after 30 min to reach maximal BRET signals 
even higher than the basal levels after 45–60 min (Figure 6C), 
suggesting the recycling of the internalized receptors and/or the 
recruitment of an intracellular pool of receptors. Such behavior 
was specific to hFSHR and hLHR, since it was not observed for 
the human vasopressin 2 receptor (hV2R–Rluc8) activated with 
1 μM of AVP (Figure 6C). In fact, these data are consistent with 
a delayed internalization (maximum after 30 min) and absence 
of recycling to the plasma membrane after internalization as 
it is well documented for V2R (48–50). Moreover, in order to 
estimate the kinetic parameter of the receptor recycling, we 
normalized the part of the curves corresponding to the recovery 
phase of hFSHR and hLHR shown in Figure 6C by taking 0 and 
100% of the maximal BRET changes measured after 2 (maximal 
internalization) and 60 min of stimulation (maximal recycling), 
respectively (Figure  6D). As a result, both receptors recycled 
with similar kinetics with a half-time of about 10 min (Table 1), 
indicating that the recycling of hFSHR and hLHR was slower than 
their internalization, at least in our system. Finally, we performed 
BRET dose–response experiments after 5  min of stimulation 
showing the decrease in the BRET signals between Rluc8-tagged 
receptors and Venus-KRas in a dose-dependent manner with no 
significant differences between the two receptors (Figure 6E). It 
is worth noting that the potencies of hFSH and hCG on receptor 
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FigUre 2 | FreT-based caMP production assays. (a) Principle of the 
FRET-based cAMP assay (ICUE sensor). HEK 293 cells transiently 
co-expressing ICUE sensor with either hFSHR or hLHR (e) were used for 
FRET measurements using either 96-well format (B–D) or microscopy on 
individual cells (e). Cells were stimulated with either 1 μM of forskolin 
(B,e), 5 nM of hFSH (c), 1 nM of hFSH or hCG (e), or vehicle (D) as 
indicated. Then FRET measurements were performed as described in the 
Section “Materials and Methods.” Data are representative of three 
independent experiments performed in single points (B–D) or 16 individual 
cells (e).
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internalization were similar to that observed for the recruitment 
of β-arrestin 2 (Figures 5D,E; Table 1), consistent with the notion 
that both events may be linked.
Discussion
In this study, we provide new insights on the activation and regula-
tion of gonadotropin receptors by applying energy transfer-based 
technologies (BRET and FRET). These aspects were studied in 
real-time in live HEK 293 cells in dose- and time-dependent man-
ners using various BRET configurations and BRET/FRET sensors. 
This allowed us to cover critical steps in the signaling of hFSHR 
and hLHR going from their intimate coupling to the heterotrimeric 
Gαs/Gβγ proteins at the membrane to the accumulation of cyto-
solic cAMP and calcium as well as β-arrestin 2 recruitment, recep-
tor internalization, and recycling. Together, our data illustrate the 
robustness of the different BRET and FRET assays used to examine 
such components of GPCR activation and signaling with exquisite 
precision. In our hand, FRET, which gives beautiful results in 
fluorescence microscopy, is less suited to multiwell plate measure-
ments than BRET since it displayed highly reduced amplitude of 
response. However, FRET sensors combined with microscopy 
offers the advantage of measuring individual cell responses.
The set of data presented in this study on hFSHR and hLHR 
confirm and expand previous reports from the literature using con-
ventional approaches in terms of G protein-dependent signaling, 
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FigUre 3 | g protein activation assessed by BreT. (a) Principle of 
the BRET-based G protein assay. HEK 293 cells transiently co-expressing 
the indicated Rluc8- and Venus-fused G protein subunits with either 
hFSHR (B,D) or hLHR (c,e) were used for BRET measurements using 
96-well format performed before and after injection of 10 nM hFSH 
or hCG as described in the Section “Materials and Methods.” Data 
are representative of three independent experiments performed in 
single points.
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β-arrestin recruitment, and receptor trafficking. Indeed, a high 
potency (picomolar range) (Table 1) was classically observed for 
both hFSH and hCG with respect to the activation of the canoni-
cal Gs/cAMP signaling pathway, which is thought to account for 
the most physiological responses of FSH and LH in the gonads, 
hence in the control of reproduction (1, 2, 8). BRET measurements 
between the Gαs and Gβγ subunits activated by hFSHR and hLHR 
showed relatively rapid BRET changes upon receptor activation 
consistent with previous observations using similar BRET assays on 
different heterotrimeric G proteins and GPCRs (32, 33, 35, 36, 51). 
Moreover, BRET-based calcium sensor allowed the assessment of 
rapid and transient calcium release in response to the hormones 
confirming previous reports of FSHR- and LHR-mediated calcium 
response (37, 38). Moreover, our data suggest differences between 
the two receptors in terms of the basal calcium response, and 
further investigation will be needed to better understand this 
aspect of FSHR/LHR signaling. One possible explanation could 
be that the higher basal level observed in LHR-transfected cells is a 
reflexion of the fact that this receptor leads to significant constitu-
tive activity while FSHR does not (52, 53).
Interestingly, our BRET data provide the first direct evidence 
for the dynamics of receptor/β-arrestin association, in real-time 
and live cells, in response to FSH and hCG stimulation. We 
confirmed the accuracy of the measurements for hFSHR/β-
arrestin association using an indirect TANGO assay, both data 
sets being also consistent with those recently reported on FSHR 
using the PathHunter β-arrestin assay from DiscoverRx (4, 5). 
This commercial assay, similar to our home-made TANGO assay, 
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FigUre 4 | BreT-based calcium assay. (a) Principle of the BRET-
based calcium assay. HEK 293 cells transiently co-expressing the 
AEQ-GFP sensor with either hFSHR (B,D,e) or hLHR (c) were used for 
light emission measurements using 96-well format before and after 
injection of vehicle (D) 10 nM hFSH or hCG or various doses of hFSH (e) 
as described in the Section “Materials and Methods.” Data are 
representative of three independent experiments performed in single 
points.
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precludes real-time measurements since 90 min of agonist stimu-
lation are followed by 1 h of incubation before the assay detection 
(overnight incubation in the TANGO assay). In addition, it is 
worth noting that non-trivial modifications are introduced in the 
C-terminus of FSHR in these two assays, although this region 
is known to be critical for receptor phosphorylation by GRKs 
and β-arrestin interaction. The real-time kinetic analysis using 
BRET showed a time-dependent increase in β-arrestin 2 recruit-
ment with a plateau reached after 20–30  min of stimulation 
consistent with previous BRET data on β-arrestin recruitment 
to other GPCRs (26, 27, 33, 34, 51, 54). The sustained BRET 
signals induced after 20–50  min of stimulation suggests that 
hFSHR and hLHR present a class B GPCR profile similarly to 
the prototypic vasopressin V2 receptor (41, 46). In addition, the 
BRET data on β-arrestin 2 recruitment were nicely correlated 
with the internalization data in terms of efficiency and to some 
extent kinetics (Figure  7; Table  1). This is consistent with the 
previously reported central role played by β-arrestins in the 
internalization of hFSHR and hLHR (55, 56) and fits well with the 
classical paradigm of GPCR trafficking (41, 42, 57, 58). However, 
our real-time BRET analysis on both receptors clearly showed 
receptor recycling and/or recruitment of new receptors at the 
plasma membrane as indicated by a recovery of BRET signals 
occurring after 10 min of stimulation and reaching a maximum 
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FigUre 5 | β-arrestin 2 recruitment assessed by BreT. (a). Principle 
of the BRET-based β-arrestin assay. HEK 293 cells transiently co-
expressing yPET-β-arrestin 2 with either hFSHR-Rluc8 (B,e,g), hLHR-Rluc8 
(c,F) or hV2R–Rluc8 (D) were used for BRET measurements in 96-well 
format using both real-time kinetics under basal (vehicle) and stimulated 
conditions in the presence of 10 nM of hormones (B,c) and endpoint signal 
recording after 30 min of stimulation with increasing hormone 
concentrations (D–F) as described in the Section “Materials and Methods.” 
In parallel, hFSHR/β-arrestin 2 association was also assessed in dose-
dependent way using TANGO assay in 384-well format (g). Data are 
means ± SEM of three to four independent experiments performed in 
triplicate points.
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higher than the basal level after 45–60 min. Such an observation 
was specific to hFSHR and hLHR since the internalization of 
hV2R was significantly delayed with no recycling of the receptor 
observed, as previously reported for this receptor (48–50). This 
difference with V2R suggests that the trafficking of hFSHR and 
hLHR is more complex than their simple classification into class 
A versus B GPCRs. In fact, the recovery phase observed with 
hFSHR and hLHR may be explained either by the recycling of the 
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(a) Principle of the BRET-based receptor internalization assay. HEK 293 cells 
transiently co-expressing Venus-KRas with either hFSHR-Rluc8, hLHR-Rluc8, 
or hV2R–Rluc8 were used for BRET measurements using 96-well format as 
described the Section “Materials and Methods.” Real-time kinetics (B) and 
dose–response analysis (e) after 2 min of stimulation with 10 nM (B) or 
increasing concentrations (e) of the hormones. In addition, time-course 
experiments were performed upon cell stimulation with 10 nM of the 
indicated agonists for 2, 5, 10, 20, 30, 45, and 60 min (c). The BRET 
recovery phases for hFSHR and hLHR in (c) were also fitted using a 
non-linear regression (one phase kinetic equation) and by taking the signals 
after 2 and 60 min as 0 and 100% of recovery, respectively (D). This allowed 
the calculation of t1/2 values of receptor recycling indicated in Table 1. Data 
are means ± SEM of three independent experiments performed in triplicate 
points. *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant compared to 
unstimulated controls.
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internalized receptors as previously shown for FSHR (44, 59) and 
LHR (60), or by the mobilization of a new intracellular pool of 
“spare receptors” or “receptor reserve” to the plasma membrane, 
or a combination of both processes. Beside, both FSHR and LHR 
have been reported to traffic through pre-early endosomes (60). 
This unusual trafficking may explain the fast internalization and 
recycling observed in our system.
To get a better picture of what happens with hFSH and hLHR 
in terms of activation, desensitization, and internalization, we 
normalized the dose-dependent responses of both receptors with 
regard to cAMP pathway, β-arrestin 2 recruitment, and receptor 
internalization assessed by different BRET assays reported in 
this study (Figure 7). For both hFSHR (Figure 7A) and hLHR 
(Figure 7B), we found a spectacular left-warded shift (about three 
logs) of cAMP curve (EC50 ≈ pM) as compared to β-arrestin 2 and 
internalization curves (EC50 ≈ nM), indicating the high efficiency 
of gonadotropins for this signaling pathway. In contrast, there was 
no difference between β-arrestin 2 recruitment and internalization 
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FigUre 7 | comparative analysis of the dose–response analysis on 
caMP responses, β-arrestin 2 recruitment, and receptor internalization. 
For both hFSHR (a) and hLHR (B), the individual dose–response data obtained 
in each BRET assay were normalized to the maximal signal taken as 100% of 
receptor-mediated responses. Moreover, receptor occupancy curves were 
incorporated to correlate the different specific responses with the percentage 
of occupied receptor. The occupancy was estimated using the following 
equation: % Occupancy = (Ligand)/(Ligand) + Kd, considering a Kd of 2 nM for 
both hFSH and hCG determined by radioligand binding assay on hFSHR 
expressed in HEK 293 cells (data not shown).
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curves since both processes are tightly linked. Such a shift cannot 
be due to the fusion of the receptors with Rluc8 since both hFSHR-
Rluc8 and hLHR-Rluc8 respond to gonadotropin stimulation 
with similar potencies as their respective unmodified receptors 
as shown by BRET (Figures 1D,E) and HTRF® (Figures 1F,G) 
assays. In addition, dose–response curves of receptor internaliza-
tion using BRET with KRas were similar to that for β-arrestin 2 
recruitment even though no yPET-β-arrestin overexpression was 
used in the internalization assay, ruling out the possibility that the 
shift observed for β-arrestin 2 recruitment could reflect a dimin-
ished functionality of the yPET-β-arrestin 2 (Figures 5E and 7) or 
the modified variant in TANGO assay (Figure 5G).
Interestingly, the predicted receptor occupancy curves, using 
a Kd of 2 nM determined by radioligand binding assay on HEK 
293 cells stably expressing hFSHR, indicated that <10% of the 
activated receptors is sufficient to promote maximal cAMP 
response whereas more than 90% of the receptors needed to be 
occupied to have full β-arrestin 2 recruitment as well as receptor 
internalization (Figures 7A,B). Noteworthy, our measurements 
of the rapid internalization phase displayed maximal response 
in the nanomolar range for both receptors, demonstrating that 
the full complement of receptor is accessible to hormone bind-
ing, even at early stimulation times. This observation rules out 
the scenario where only a limited fraction of receptors would 
be present at the plasma membrane at the time of stimulation. 
Together with the recycling data shown in Figure 6, our results are 
in accordance with the concept of “spare receptors,” postulating 
that for high-efficacy hormones, a small population of receptors 
occupied is sufficient to fully promote the biological response 
(61–63), a paradigm, which has also been previously evoked 
for gonadotropin receptors (61, 64–66). The “spare receptors” 
concept predicates that there is a mechanism by which only small 
amount of gonadotropin receptors needs to be occupied to fully 
elicit cAMP-dependent function of the gonadotropin hormones. 
This is consistent with the well-established amplification of the 
intracellular cAMP signaling pathway and suggests a model where 
Gαs and/or adenylyl cyclase would be limiting yet accessible to all 
the occupied receptors in the cells. Alternatively, the existence of 
pre-assembled receptor-G protein complexes, as demonstrated 
for many GPCR-G protein pairs (27, 51, 67–69), may explain 
such an observation. Indeed, a limited amount of pre-assembled 
complexes could preferentially bind hormones by virtue of its 
well-established affinity increase for the ligand within the ternary 
complex (70). In contrast, β-arrestin recruitment and receptor 
internalization processes are remarkably proportional to receptor 
occupancy, suggesting that neither mechanism is amplified but 
rather that they depend on a 1:1 stoichiometric interaction with 
the receptors. Moreover, the differences in hormone potencies and 
receptor efficacies between cAMP and β-arrestin 2 recruitment/
internalization pathways may explain the balance between recep-
tor activation and receptor desensitization but also the balance 
between G protein-dependent and β-arrestin-dependent signal-
ing pathways. Therefore, further investigation will be required 
to better dissect these aspects of FSHR and LHR trafficking and 
their putative link with the G protein- and β-arrestin-dependent 
downstream signaling in the gonads in physiological and patho-
physiological settings. From the technological point of view, 
our study illustrates the advantage of applying BRET and FRET 
approaches to study the signaling and trafficking of FSHR and 
LHR in real-time and live cells. Of course, these approaches are 
based on transient expression of fusion proteins of the receptors 
and their different signaling and regulatory partners. Therefore, 
it will be important in the future, to apply other methods in order 
to confirm our observations in cells or native tissues expressing 
unmodified receptors and regulatory proteins at endogenous 
levels. Despite these potential shortcomings, the assays presented 
here may nonetheless have considerable potential for pharmaco-
logical profiling of gonadotropin receptors.
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